Teva subsidiaries price $3.2 billion and €1.5 billion in new senior notes
Teva Pharmaceutical Finance units issued five tranches of notes on September 16, 2026, with proceeds set to fund redemptions of existing debt.
SEC filing
Latest
15 stories
Thursday, September 17
Wednesday, September 16
Friday, September 11
Teva gets labeling supplement approved for injectable Paclitaxel
Tuesday, September 8
Teva prices multi-tranche notes offering to fund redemption of five outstanding bond series
Teva's Dutch finance subsidiaries plan euro and dollar notes due 2032 through 2037, with proceeds earmarked to redeem called notes and repay debt.
SEC filing
Thursday, September 3
Vaxcyte names new chief medical and legal officers, moves up OPUS-1 data timing
Luis Jodar joins as CMO and David McAvoy as CLO as Vaxcyte says VAX-31 Phase 3 topline data will arrive by end of October 2026 instead of the fourth quarter.
SEC filing
Wednesday, September 2
Actavis Labs FL secures four labeling supplement approvals for bupropion HCl SR
Monday, August 31
FDA accepts BLA for Alvotech's AVT80, a subcutaneous Entyvio biosimilar candidate
The filing covers a proposed interchangeable biosimilar to vedolizumab in prefilled syringe and autoinjector form, adding to Alvotech's intravenous candidate AVT16.
SEC filing
Friday, August 21
Teva gets FDA approval for generic tofacitinib citrate ER; two Claravis labeling supplements cleared
Friday, August 14
FDA clears five ANDA supplements for Teva and Actavis Labs generics, mostly labeling updates
Friday, August 7
Actavis Labs UT's clindamycin/benzoyl peroxide gel ANDA shows FDA approval letter dated August 20, 2
Wednesday, July 29
Teva posts Q2 2026 GAAP loss on Emalex charge, raises innovative brand outlook
Teva reported a $576 million net loss tied to the Emalex acquisition and ecopipam NDA filing, while raising its 2026 revenue outlook for AUSTEDO, AJOVY and UZEDY.
SEC filing
Teva gets ANDA approval for sugammadex sodium injection; four mycophenolate REMS updates cleared
Tuesday, July 28
Nasus Pharma names Brendan P. O'Grady CEO, succeeding Dan Teleman
The intranasal drug developer said O'Grady will focus on NS002 commercialization ahead of a planned pivotal trial and 2027 data readout.
SEC filing